Radiation and Ethylene Oxide Terminal Sterilization Experiences with Drug Eluting Stent Products

被引:55
|
作者
Lambert, Byron J. [1 ]
Mendelson, Todd A. [1 ]
Craven, Michael D. [2 ]
机构
[1] Abbott Vasc, R&D, Temecula, CA 92589 USA
[2] Abbott Vasc, R&D, Santa Clara, CA USA
来源
AAPS PHARMSCITECH | 2011年 / 12卷 / 04期
关键词
combination devices; drug eluting stents; ethylene oxide sterilization; material compatibility; radiation sterilization; LESIONS RANDOMIZED-TRIALS; CORONARY-ARTERY LESIONS; CLINICAL-EVALUATION; SYSTEM EECSS; SPIRIT III; EVEROLIMUS; DEVICES;
D O I
10.1208/s12249-011-9644-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Radiation and ethylene oxide terminal sterilization are the two most frequently used processes in the medical device industry to render product within the final sterile barrier package free from viable microorganisms. They are efficacious, safe, and efficient approaches to the manufacture of sterile product. Terminal sterilization is routinely applied to a wide variety of commodity healthcare products (drapes, gowns, etc.) and implantable medical devices (bare metal stents, heart valves, vessel closure devices, etc.) along with products used during implantation procedures (catheters, guidewires, etc.). Terminal sterilization is also routinely used for processing combination products where devices, drugs, and/or biologics are combined on a single product. High patient safety, robust standards, routine process controls, and low-cost manufacturing are appealing aspects of terminal sterilization. As the field of combination products continues to expand and evolve, opportunity exists to expand the application of terminal sterilization to new combination products. Material compatibility challenges must be overcome to realize these opportunities. This article introduces the reader to terminal sterilization concepts, technologies, and the related standards that span different industries (pharmaceutical, medical device, biopharmaceuticals, etc.) and provides guidance on the application of these technologies. Guidance and examples of the application of terminal sterilization are discussed using experiences with drug eluting stents and bioresorbable vascular restoration devices. The examples provide insight into selecting the sterilization method, developing the process around it, and finally qualifying/validating the product in preparation for regulatory approval and commercialization. Future activities, including new sterilization technologies, are briefly discussed.
引用
收藏
页码:1116 / 1126
页数:11
相关论文
共 41 条
  • [41] Usefulness of Preprocedural Levels of Advanced Glycation End Products to Predict Restenosis in Patients With Controlled Diabetes Mellitus Undergoing Drug-Eluting Stent Implantation for Stable Angina Pectoris (From the Prospective ARMYDA-AGEs Study)
    Spadaccio, Cristiano
    Patti, Giuseppe
    De Marco, Federico
    Coccia, Raffaella
    Di Domenico, Fabio
    Pollari, Francesco
    Zanzonico, Roberta
    Pettinari, Matteo
    Lusini, Mario
    Di Sciascio, Germano
    Covino, Elvio
    Chello, Massimo
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (01): : 21 - 26